These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pathogenesis and animal studies of Parkinson's disease. Oertel WH, Kupsch A. Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901 [Abstract] [Full Text] [Related]
3. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Chiueh CC, Miyake H, Peng MT. Adv Neurol; 1993 Jun; 60():251-8. PubMed ID: 8380519 [No Abstract] [Full Text] [Related]
4. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ. Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758 [Abstract] [Full Text] [Related]
5. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Novikova L, Garris BL, Garris DR, Lau YS. Neuroscience; 2006 Jun 19; 140(1):67-76. PubMed ID: 16533572 [Abstract] [Full Text] [Related]
10. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Muñoz A, Rey P, Guerra MJ, Mendez-Alvarez E, Soto-Otero R, Labandeira-Garcia JL. Neuropharmacology; 2006 Jul 19; 51(1):112-20. PubMed ID: 16678218 [Abstract] [Full Text] [Related]
11. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys. Goulet M, Morissette M, Grondin R, Falardeau P, Bédard PJ, Rostène W, Di Paolo T. Synapse; 1999 Jun 01; 32(3):153-64. PubMed ID: 10340626 [Abstract] [Full Text] [Related]
14. Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter. Calon F, Lavertu N, Lemieux AM, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bédard PJ, Di Paolo T. Synapse; 2001 Jun 01; 40(3):225-34. PubMed ID: 11304760 [Abstract] [Full Text] [Related]
16. Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice. Mash DC, Pablo J, Buck BE, Sanchez-Ramos J, Weiner WJ. Exp Neurol; 1991 Oct 01; 114(1):73-81. PubMed ID: 1915737 [Abstract] [Full Text] [Related]
17. A cloned dopamine transporter. Potential insights into Parkinson's disease pathogenesis. Uhl GR, Kitayama S. Adv Neurol; 1993 Oct 01; 60():321-4. PubMed ID: 8380524 [No Abstract] [Full Text] [Related]
18. Selective alterations of gene expression in mice induced by MPTP. Xu Z, Cawthon D, McCastlain KA, Slikker W, Ali SF. Synapse; 2005 Jan 01; 55(1):45-51. PubMed ID: 15499605 [Abstract] [Full Text] [Related]
19. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa. Poyot T, Condé F, Grégoire MC, Frouin V, Coulon C, Fuseau C, Hinnen F, Dollé F, Hantraye P, Bottlaender M. J Cereb Blood Flow Metab; 2001 Jul 01; 21(7):782-92. PubMed ID: 11435790 [Abstract] [Full Text] [Related]
20. Metabolic aspects of the behavior of MPTP and some analogues. Tipton KF, McCrodden JM, Sullivan JP. Adv Neurol; 1993 Jul 01; 60():186-93. PubMed ID: 8420134 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]